OppenheimerFunds Inc. lowered its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 13.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 162,539 shares of the company’s stock after selling 25,007 shares during the period. OppenheimerFunds Inc.’s holdings in IDEXX Laboratories were worth $36,344,000 at the end of the most recent reporting period.
Several other hedge funds have also recently made changes to their positions in the company. Private Advisor Group LLC raised its holdings in shares of IDEXX Laboratories by 54.1% in the first quarter. Private Advisor Group LLC now owns 4,156 shares of the company’s stock valued at $851,000 after purchasing an additional 1,459 shares during the last quarter. State of Wisconsin Investment Board raised its holdings in shares of IDEXX Laboratories by 4.2% in the first quarter. State of Wisconsin Investment Board now owns 91,586 shares of the company’s stock valued at $20,479,000 after purchasing an additional 3,729 shares during the last quarter. Thompson Siegel & Walmsley LLC raised its holdings in shares of IDEXX Laboratories by 1,228.1% in the first quarter. Thompson Siegel & Walmsley LLC now owns 5,299 shares of the company’s stock valued at $1,185,000 after purchasing an additional 4,900 shares during the last quarter. Fundsmith LLP raised its holdings in shares of IDEXX Laboratories by 0.8% in the first quarter. Fundsmith LLP now owns 4,467,341 shares of the company’s stock valued at $998,897,000 after purchasing an additional 35,049 shares during the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of IDEXX Laboratories by 36.7% in the first quarter. Principal Financial Group Inc. now owns 1,076,895 shares of the company’s stock valued at $240,793,000 after purchasing an additional 289,063 shares during the last quarter. Institutional investors own 87.76% of the company’s stock.
A number of analysts recently issued reports on the stock. Guggenheim assumed coverage on shares of IDEXX Laboratories in a report on Thursday, May 23rd. They set a “buy” rating and a $276.00 price objective for the company. BidaskClub upgraded shares of IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 7th. Canaccord Genuity raised their price objective on shares of IDEXX Laboratories from $255.00 to $260.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Finally, Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $271.00 price objective for the company in a report on Friday, May 3rd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. IDEXX Laboratories presently has an average rating of “Buy” and an average price target of $256.71.
NASDAQ IDXX traded up $0.46 during trading hours on Wednesday, reaching $264.39. 4,888 shares of the company were exchanged, compared to its average volume of 497,105. IDEXX Laboratories, Inc. has a 1 year low of $176.11 and a 1 year high of $271.34. The company has a debt-to-equity ratio of 14.81, a quick ratio of 0.74 and a current ratio of 1.01. The company has a market capitalization of $22.80 billion, a PE ratio of 62.09 and a beta of 0.84.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported $1.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.04 by $0.13. IDEXX Laboratories had a net margin of 17.33% and a return on equity of 354,783.84%. The business had revenue of $576.06 million during the quarter, compared to the consensus estimate of $575.04 million. During the same quarter last year, the company posted $1.01 earnings per share. The firm’s quarterly revenue was up 7.1% compared to the same quarter last year. As a group, analysts forecast that IDEXX Laboratories, Inc. will post 4.82 EPS for the current fiscal year.
In other news, insider Giovani Twigge sold 2,600 shares of IDEXX Laboratories stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $250.14, for a total value of $650,364.00. Following the completion of the transaction, the insider now owns 12,595 shares in the company, valued at $3,150,513.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Jonathan W. Ayers sold 28,000 shares of IDEXX Laboratories stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $249.02, for a total transaction of $6,972,560.00. The disclosure for this sale can be found here. Insiders have sold 50,721 shares of company stock valued at $12,554,774 in the last 90 days. 2.70% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “OppenheimerFunds Inc. Has $36.34 Million Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)” was originally reported by Transcript Daily and is the property of of Transcript Daily. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://transcriptdaily.com/2019/06/12/oppenheimerfunds-inc-has-36-34-million-stake-in-idexx-laboratories-inc-nasdaqidxx.html.
IDEXX Laboratories Profile
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
Featured Story: Earnings Reports
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.